UNSPSC 51111843: Deslorelin

This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C64H83N17O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TKG3I66TVE, chemically known as 1-9-luteinizing hormone-releaasing factor (swine), 6-d-tryptophan-9-(n-ethyl-l-prolinamide)- but generally known as deslorelin, which bears US NIH Compound Identifier 16129697. European Medicines Agency schedules Deslorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06998MIG.

UNSPSC 51111843 Deslorelin, a Commodity code, encompasses active pharmaceutical ingredients and finished-dose pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and direct solicitations for distribution across health departments, correctional facilities, public health clinics, and other government-operated medical settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body for this code, soliciting generic multi-source pharmaceuticals and over-the-counter products on behalf of multiple participating state and local government entities across jurisdictions including Minnesota and Oregon. Work under the code involves manufacturers providing comprehensive product specifications including National Drug Codes (NDCs), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations, with all products required to comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements. Vendors must maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), possess chargeback systems, and offer flexible pricing through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures.

MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, represents the primary recent opportunity under the code. The solicitation emphasizes price competitiveness (75 percent of evaluation weight), compliance with administrative fee data format requirements and EDI capability (5 percent each), fixed pricing stability (10 percent), and commitment to a 3 percent administrative fee (5 percent). Contract awards will be effective July 1, 2026, with a two-year initial term for new responders and optional extensions at MMCAP's discretion; incumbent responders' amendments extend through June 30, 2028. Vendors must maintain comprehensive insurance coverage including $5 million commercial general liability per occurrence, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.